At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
QURE uniQure NV
Pre-Mkt 05-27 04:00:34 EDT
25.15
+0.96
+3.97%
盘前24.50
-0.65-2.58%
04:00 EDT
High25.52Low24.00Vol1.22M
Open24.41D1 Closing24.19Amplitude6.28%
Mkt Cap1.59BTradable Cap1.25BTotal Shares63.03M
T/O30.53MT/O Rate2.46%Tradable Shares49.72M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

A Look At uniQure (QURE) Valuation After AMT-130 Gene Therapy Regulatory Plans And Trial Update
Simply Wall St.  ·  05-25 20:13
A Look At uniQure (QURE) Valuation After AMT-130 Gene Therapy Regulatory Plans And Trial Update
Biotech Investors Are Tuning Out the MAHA Chaos -- Heard on the Street -- WSJ
Dow Jones  ·  05-20
Biotech Investors Are Tuning Out the MAHA Chaos -- Heard on the Street -- WSJ
Makary exit may temporarily lift biotech sentiment but FDA leadership vacuum looms
Reuters  ·  05-14
Makary exit may temporarily lift biotech sentiment but FDA leadership vacuum looms
BUZZ-U.S. STOCKS ON THE MOVE-Nebius, US chipmakers, Assertio Holdings
Reuters  ·  05-13
BUZZ-U.S. STOCKS ON THE MOVE-Nebius, US chipmakers, Assertio Holdings
uniQure CMO Walid Abi-Saab sells USD 1.13 million in shares
Reuters  ·  05-13
uniQure CMO Walid Abi-Saab sells USD 1.13 million in shares
Stock Track | uniQure NV Soars 6.87% Intraday as FDA Commissioner Announces Resignation
Stock Track  ·  05-13
Stock Track | uniQure NV Soars 6.87% Intraday as FDA Commissioner Announces Resignation
BUZZ-U.S. STOCKS ON THE MOVE-Tyler Technologies, Autodesk, Illumina
Reuters  ·  05-13
BUZZ-U.S. STOCKS ON THE MOVE-Tyler Technologies, Autodesk, Illumina
BUZZ-Replimune, uniQure rise; FDA commissioner Makary plans to resign
Reuters  ·  05-13
BUZZ-Replimune, uniQure rise; FDA commissioner Makary plans to resign
uniQure price target lowered to $50 from $70 at H.C. Wainwright
TIPRANKS  ·  05-07
uniQure price target lowered to $50 from $70 at H.C. Wainwright
uniQure Is Maintained at Buy by HC Wainwright & Co.
Dow Jones  ·  05-07
uniQure Is Maintained at Buy by HC Wainwright & Co.
Goldman Sachs Sticks to Its Hold Rating for uniQure (QURE)
TIPRANKS  ·  05-06
Goldman Sachs Sticks to Its Hold Rating for uniQure (QURE)
Chardan Capital Remains a Buy on uniQure (QURE)
TIPRANKS  ·  05-06
Chardan Capital Remains a Buy on uniQure (QURE)
Analysts’ Top Healthcare Picks: Spyre Therapeutics (SYRE), uniQure (QURE)
TIPRANKS  ·  05-06
Analysts’ Top Healthcare Picks: Spyre Therapeutics (SYRE), uniQure (QURE)
Uniqure NV reports results for the quarter ended March 31 - Earnings Summary
Reuters  ·  05-05
Uniqure NV reports results for the quarter ended March 31 - Earnings Summary
Earnings Flash (QURE) UniQure Posts Q1 Net Loss $0.85 a Share, vs. FactSet Est of $0.85 Loss
MT Newswires Live  ·  05-05
Earnings Flash (QURE) UniQure Posts Q1 Net Loss $0.85 a Share, vs. FactSet Est of $0.85 Loss
uniQure Q1 EPS $(0.85), Inline, Sales $3.562M Miss $5.223M Estimate
Benzinga  ·  05-05
uniQure Q1 EPS $(0.85), Inline, Sales $3.562M Miss $5.223M Estimate
uniQure Announces First Quarter 2026 Financial Results and Provides Recent Company Updates
GlobeNewswire  ·  05-05
uniQure Announces First Quarter 2026 Financial Results and Provides Recent Company Updates
A Look At uniQure (QURE) Valuation After AMT-130 Regulatory Progress With The MHRA
Simply Wall St.  ·  05-04
A Look At uniQure (QURE) Valuation After AMT-130 Regulatory Progress With The MHRA
uniQure Is Maintained at Buy by Chardan Capital
Dow Jones  ·  05-01
uniQure Is Maintained at Buy by Chardan Capital
uniQure price target raised to $37 from $31 at Chardan
TIPRANKS  ·  05-01
uniQure price target raised to $37 from $31 at Chardan

Introduction

Company Name.
uniQure NV
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Issue price:
--